Motor and Nonmotor Features of Carriers of the p.A53T Alpha-Synuclein Mutation: A Longitudinal Study

Movement Disorders

Volumn 31, Issue 8, 2016, Pages 1226-1230

  Papadimitriou, Dimitra ^a,b   Antonelou, Roubina ^c   Miligkos, Michael ^d   Maniati, Matina ^b   Papagiannakis, Nikolaos ^b,c   Bostantjopoulou, Sevasti ^e   Leonardos, Athannassios ^c   Koros, Christos ^c   Simitsi, Athina ^c   Papageorgiou, Sokratis G ^c   Kapaki, Elisabeth ^f   Alcalay, Roy N ^g   Papadimitriou, Alexandros ^a   Athanassiadou, Aglaia ^h   Stamelou, Maria ^c,i,j   Stefanis, Leonidas ^b,c  

^a HENRY DUNANT HOSPITAL   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF THESSALY   (Greece)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^g Department of Medicine   (United States)

^h UNIVERSITY OF PATRAS   (Greece)

ⁱ PHILIPPS UNIVERSITY MARBURG   (Germany)

^j HYGEIA HOSPITAL   (Greece)

more..

Author keywords

A53T; alpha synuclein; asymptomatic; Parkinson's disease; penetrance

Indexed keywords

ALPHA SYNUCLEIN; SNCA PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DEMENTIA; DEPRESSION; DISEASE DURATION; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC RISK; HETEROZYGOTE; HUMAN; LONGITUDINAL STUDY; MALE; MENTAL DETERIORATION; ONSET AGE; PARASOMNIA; PARKINSON DISEASE; PENETRANCE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; SEX DIFFERENCE; SLEEP DISORDER; SMELLING DISORDER; UNIFIED PARKINSON DISEASE RATING SCALE; VERY ELDERLY; AUTONOMIC NEUROPATHY; COMPLICATION; GENETICS; MIDDLE AGED; MUTATION; PATHOPHYSIOLOGY; PSYCHOSIS;

ADULT; AGED; ALPHA-SYNUCLEIN; AUTONOMIC NERVOUS SYSTEM DISEASES; DEMENTIA; FEMALE; HETEROZYGOTE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION; OLFACTION DISORDERS; PARKINSON DISEASE; PENETRANCE; PSYCHOTIC DISORDERS;

EID: 84963811810     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26615     Document Type: Article

References (24)

1. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
2. Kasten M, Klein C. The many faces of alpha-synuclein mutations. Mov Disord 2013;28:697-701.
3. Choi JM, Woo MS, Ma HI, et al. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics 2008;9:263-269.
4. Puschmann A, Ross OA, Vilariño-Güell C, et al. A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat Disord 2009;15:627-632.
5. Bostantjopoulou S, Katsarou Z, Papadimitriou A, Veletza V, Hatzigeorgiou G, Lees A. Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. Mov Disord 2001;16:1007-1013.
6. Papadimitriou A, Veletza V, Hadjigeorgiou GM, Patrikiou A, Hirano M, Anastasopoulos I. Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? Neurology 1999;52:651-654.
7. Papapetropoulos S, Ellul J, Paschalis C, Athanassiadou A, Papadimitriou A, Papapetropoulos T. Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece. Eur J Neurol 2003;10:281-286.
8. Papapetropoulos S, Paschalis C, Athanassiadou A, et al. Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:662-665.
9. Morfis L, Cordato DJ. Dementia with Lewy bodies in an elderly Greek male due to alpha-synuclein gene mutation. J Clin Neurosci 2006;13:942-944.
10. Bozi M, Papadimitriou D, Antonellou R, et al. Genetic assessment of familial and early-onset Parkinson's disease in a Greek population. Eur J Neurol 2014;21:963-968.
11. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010;75:1717-1725.
12. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psych Rev 1988;8:77-100.
13. Hummel T, Kobal G, Gudziol H, Mackay-Sim A. Normative data for the “Sniffin' Sticks” including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol 2007;264:237-243.
14. Marder K, Wang Y, Alcalay RN, et al. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology 2015;85:89-95.
15. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J Neural Transm 2000;107:59-71.
16. Lang AE, Eberly S, Goetz CG, et al. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov Disord 2013;28:1980-1986
17. Nabli F, Ben Sassi S, Duda JE, Farrer MJ, Hentati F. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study. Mov Disord 2015;30:253-258
18. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001;58:1611-1615.
19. Golbe LI, Di Iorio G, Sanges G, et al. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol 1996;40:767-775.
20. Markopoulou K, Wszolek ZK, Pfeiffer RF. A Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation. Ann Neurol 1995;38:373-378.
21. Athanassiadou A, Voutsinas G, Psiouri L, et al. Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. Am J Hum Genet 1999;65:555-558.
22. Trinh J, Guella I, Farrer M. Disease penetrance of late-onset parkinsonism: a meta-analysis. JAMA Neurol 2014;71:1535-1539.
23. Papapetropoulos S, Paschalis C, Ellul J, Papapetropoulos T, Athanassiadou A. Survival duration of Parkinson's disease patients living in Greece who carry the G209A alpha-synuclein mutation. Mov Disord 2002;17:847-848.
24. Schneeberger A, Mandler M, Mattner F, Schmidt W. Vaccination for Parkinson's disease. Parkinsonism Relat Disord 2012;18(Suppl 1):S11-S13.